Sakar Healthcare is a pharmaceutical company that has turned a single, early-career contract manufacturing relationship into a fully integrated, research-driven oncology engine. Founded in 2004 by a first-generation entrepreneur making oral liquids for Zydus, the company now operates a vertically integrated facility where it develops the active pharmaceutical ingredient (API), the finished cancer tablet or injection, and the regulatory dossier all under one roof. The recurring approach is a step-by-step climb up the value chain-using cash flows from generic contract manufacturing to fund a specialized oncology platform, then using that platform to win higher-margin own-brand export and licensing deals in regulated markets like Europe.
Business segments
A single pharmaceutical engine, organized into two distinct value streams-a high-margin, API-integrated oncology business built for regulated global markets, and a broad-based generics CDMO and export business that provides the industrial base and client relationships.
1. Oncology: the API-to-dossier engine targeting global cancer markets
The company makes its own cancer-drug raw materials in-house, formulates them into finished tablets and injections, and sells the resulting products through licensing and supply deals-capturing margin at every step from molecule to market.
- Makes the active ingredient itself - an in-house high-potency API plant with 12.3 metric tons of annual capacity supplies the key raw materials for its own finished cancer drugs, insulating the company from supplier dependency and allowing it to sell surplus API externally.
- One roof, three stages of production - the Bavla facility houses API manufacturing, oral solid dosage (tablets and capsules), and injectable lines (liquid and lyophilized, or freeze-dried) on a single 39,121 sq. meter campus, so the company controls quality and cost from chemistry to finished vial.
- The licence is the moat - the oncology unit holds EU GMP certification for both oral solids and injectables, a regulatory seal that unlocks the European market and is the basis for 11 marketing authorizations already granted, of which 6 are from Europe (Bulgaria and Bosnia) and 5 are from the rest of the world.
- Sells science, not just pills - the company has developed 55 oncology products and 32 ready-to-register CTD dossiers in-house, which it licenses to partners like Accord Healthcare and Torrent, earning revenue from technology transfer and dossier out-licensing before a single commercial batch is shipped.
- A pipeline built on partnerships - with over 40 agreements signed for anti-cancer products globally, including deals covering the Nordics, Central Europe, and Latin America, the company secures market access by co-developing patent non-infringing formulations with European partners and then supplying the finished product.
2. Non-oncology formulations: the CDMO and branded-export base
A broad portfolio of antibiotics, injectables, and oral liquids manufactured across four plants serves as a reliable industrial backbone, with own-brand exports now driving over 70% of total revenue.
- Four plants, many dosage forms - the Changodar campus produces cephalosporin oral solids, dry powder injections, small-volume parenterals, and oral liquids, giving the company the flexibility to manufacture across 24 therapeutic segments for a wide range of clients.
- Injectable expertise pays the bills - lyophilized and liquid injectable products contribute 60% of total sales, a concentration that reflects the company’s long-standing investment in sterile manufacturing technology like Tofflon lyophilisers with automatic loading and unloading.
- Trusted by the biggest names - the client list includes Zydus (a 20-year relationship), Intas (19 years), and Torrent (16 years), with the top five clients contributing roughly 45% of sales, creating a sticky, recurring contract manufacturing base.
- Own-brand exports are the growth lever - selling formulations under its own label across more than 60 countries, particularly in Africa, Southeast Asia, and Latin America, has shifted the revenue mix decisively toward higher-margin branded sales.
- Regulatory reach across the developing world - the company holds product registrations in over 14 countries and has been accredited by national drug authorities from Uganda to the Philippines, a footprint that allows it to distribute 321 registered products through 74 distribution partners.
Group structure and partners
The company operates through a single listed entity with one wholly owned subsidiary, Sakar Oncology Private Limited, and a strategic minority investment from a healthcare-focused private equity fund.
- A subsidiary built for regulated markets - Sakar Oncology Private Limited was incorporated in 2020 to house a facility designed to USFDA standards, positioning the group for a future entry into the United States market.
- Private equity backing with domain expertise - Tata Capital Healthcare Fund II holds a 10.82% stake acquired in September 2023, and its nominee director brings over 30 years of pharmaceutical R&D experience to the board.
- Promoter-led with skin in the game - the founding Shah family holds 53.58% of the equity, ensuring alignment between the company’s long-term, capital-intensive oncology build-out and its controlling shareholders.